Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Navitoclax (Primary) ; Vistusertib (Primary)
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 12 Apr 2019 Status changed from suspended to recruiting.
- 01 Apr 2019 Status changed from recruiting to suspended due to DLT review.
- 31 Aug 2018 Biomarkers information updated